U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C36H45N5O5S
Molecular Weight 659.838
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BECLABUVIR

SMILES

COC1=CC2=C(C=C1)C3=C(C4CCCCC4)C5=C(C=C(C=C5)C(=O)NS(=O)(=O)N(C)C)N3C[C@]6(C[C@@H]26)C(=O)N7[C@H]8CC[C@@H]7CN(C)C8

InChI

InChIKey=ZTTKEBYSXUCBSE-QDFUAKMASA-N
InChI=1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24-,25+,30-,36-/m0/s1

HIDE SMILES / InChI
Molecular Formula C36H45N5O5S
Molecular Weight 659.838
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Beclabuvir (previously known as BMS-791325), a potent, non-nucleoside inhibitor of the HCV NS5B RNA polymerase. In combination with daclatasvir and asunaprevir drug participates in clinical trials phase III for patients infected with HCV genotype 1, which is the most common genotype worldwide. Recently published data has shown that this combination achieved very high rates of viral eradication.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 0.003 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Beclabuvir for the treatment of hepatitis C.
2015
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
2018 Mar
Patents

Patents

20070270405
2
20080146537
2

Sample Use Guides

In Vivo Use Guide
Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients Other Name: Asunaprevir (ASV) and Daclatasvir (DCV) and BMS-791325 (Beclabuvir)
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:57:55 UTC 2023
Edited
by admin
on Sat Dec 16 05:57:55 UTC 2023
Record UNII
MYW1X5CO9S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BECLABUVIR
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
BMS-791325
Code English
(4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-4b,5,5a,6-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-9-carboxamide
Systematic Name English
CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-9-CARBOXAMIDE, 12-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-4B,5,5A,6-TETRAHYDRO-3-METHOXY-5A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)-, (4BS,5AR)-
Systematic Name English
BECLABUVIR [USAN]
Common Name English
Beclabuvir [WHO-DD]
Common Name English
beclabuvir [INN]
Common Name English
BECLABUVIR [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C783
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID701026084
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
DRUG CENTRAL
5215
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
PUBCHEM
56934415
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
FDA UNII
MYW1X5CO9S
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
WIKIPEDIA
Beclabuvir
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
MERCK INDEX
m11998
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
INN
9899
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
SMS_ID
100000175097
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
ChEMBL
CHEMBL3126842
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
DRUG BANK
DB12225
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
CAS
958002-33-0
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
USAN
AB-68
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
NCI_THESAURUS
C114983
Created by admin on Sat Dec 16 05:57:55 UTC 2023 , Edited by admin on Sat Dec 16 05:57:55 UTC 2023
PRIMARY
Related Record Type Details
HCV NS5B POLYMERASE
TARGET -> INHIBITOR
Structure of BECLABUVIR HYDROCHLORIDE
SALT/SOLVATE -> PARENT
HEPATITIS C VIRUS
TARGET ORGANISM->INHIBITOR
Related Record Type Details
Structure of BECLABUVIR
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966